点击蓝字关注我们一家四次冲击IPO未果的商业化药企,与一家现金即将耗尽的上市生物科技公司,在资本寒冬中携手,改写了港股18A板块的整合史。2025年4月15日,港交所披露易网站出现了一份特殊的上市申请——嘉和生物-B(06998.HK)递交主板上市申请。这不是普通的IPO,而是港股18A首例创新药企反向收购的阶段性成果。故事的两位主角分别是:四次递表、两次通过聆讯却始终未能上市的亿腾医药,以及...
Source Link点击蓝字关注我们一家四次冲击IPO未果的商业化药企,与一家现金即将耗尽的上市生物科技公司,在资本寒冬中携手,改写了港股18A板块的整合史。2025年4月15日,港交所披露易网站出现了一份特殊的上市申请——嘉和生物-B(06998.HK)递交主板上市申请。这不是普通的IPO,而是港股18A首例创新药企反向收购的阶段性成果。故事的两位主角分别是:四次递表、两次通过聆讯却始终未能上市的亿腾医药,以及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.